Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Ihekweazu, CA; Dance, DA; Pebody, R; George, RC; Smith, MD; Waight, P; Christensen, H; Cartwright, KA; Stuart, JM; South West Pneumococcus Study Group, (2008)
Publisher: Cambridge University Press (CUP)
Languages: English
Types: Article
Introduction of pneumococcal conjugate and polysaccharide vaccines into the United Kingdom's routine immunization programmes is expected to change the epidemiology of invasive pneumococcal disease (IPD). We have documented the epidemiology of IPD in an English region (South West) with high-quality surveillance data before these programmes were established. We analysed data on isolates of Streptococcus pneumoniae from blood and CSF between 1996 and 2005 from microbiology laboratories in the South West that were reported and/or referred for serotyping to the Health Protection Agency Centre for Infections. The mean annual incidence of IPD increased from 11.2/100 000 in 1996 to 13.6/100 000 in 2005 (P<0.04). After adjusting for annual blood-culture sampling rates in hospitals serving the same catchment populations, an increase in annual incidence of IPD was no longer observed (P=1.0). Variation in overall incidence between laboratories could also be explained by variation in blood culture rates. The proportion of disease caused by serotypes 6B, 9V and 14 decreased significantly (P=0.001, P=0.007, and P=0.027 respectively) whereas that caused by serotype 4, 7F and 1 increased (P=0.001, P=0.003, and P<0.001 respectively) between 2000 and 2005. The level of penicillin non-susceptibility and resistance to erythromycin remained stable (2% and 12% respectively). This study provides an important baseline to assess the impact of changing vaccination programmes on the epidemiology of IPD, thus informing future use of pneumococcal vaccines.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 3. Eriksson M, Henriques B, Ekdahl K. Epidemiology of pneumococcal infections in Swedish children. Acta Paediatrica (Suppl.) 2000 ; 89 : 35-39.
    • 4. Fenoll A, et al. Streptococcus pneumoniae in children in Spain : 1990-1999. Acta Paediatrica (Suppl.) 2000 ; 89 : 44-50.
    • 5. Gaudelus J, Cohen R, Reinert P. Epidemiology of pneumococcal infections in French children. Acta Paediatrica (Suppl.) 2000 ; 89 : 27-29.
    • 6. Kaltoft N, Zeuthen N, Konradsen HB. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark : a 19-year nationwide surveillance study. Acta Paediatrica (Suppl.) 2000 ; 89 : 3-10.
    • 7. Department of Health. Immunisation against infectious disease ; 1996 (http://www.dh.gov.uk/assetRoot/04/08/ 88/06/04088806.pdf). Accessed 1 March 2005.
    • 8. World Health Organisation. Pneumococcal vaccines. WHO position paper. Weekly Epidemiology Record 1999 ; 74 : 177-183 (http://www.who.int/wer/pdf/1999/ wer7423.pdf). Accessed 1 March 2005.
    • 9. ACIP. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Reports. Recommended Reports 2000 ; 49 (RR-9) : 1-35.
    • 10. Department of Health. Planned changes to Childhood Immunisation Programme (http://www.dh.gov.uk/ assetRoot/04/12/81/21/04128121.pdf). Accessed 22 June 2006.
    • 11. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccine. Vaccine 2003 ; 16 : 1815-1825.
    • 12. Lund E, Hendrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. In : Bergan T, Norris JR, eds. Methods in Microbiology. London : Academic Press, 1978, pp. 241-262.
    • 13. Colman G, et al. Pneumococci causing invasive disease in Britain 1982-1990. Journal of Medical Microbiology 1998 ; 47 : 17-27.
    • 14. Johnson AP, Warner M, Livermore DM. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. International Journal of Antimicrobial Agents 2001 ; 17 : 377-381.
    • 15. Andrews JM. BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 2001 ; 48 (Suppl. 1) : 43-57.
    • 16. Health Protection Agency (http://www.hpa.org.uk/ infections/topics_az/pneumococcal/Agespecificlabcases IPD.htm). Accessed 2 February 2005.
    • 17. Smith MD, et al. Invasive pneumococcal infection in South and West England. Epidemiology and Infection 1998 ; 120 : 117-123.
    • 18. George AC, Melegaro A. Invasive pneumococcal disease in England and Wales. CDR Weekly 2001 ; 11 : 4-17.
    • 19. Talbot TR, et al. Seasonality of invasive pneumococcal disease : temporal relation to documented influenza and respiratory syncytial viral circulation. American Journal of Medicine 2005 ; 118 : 285-291.
    • 20. Health Protection Agency. RCPG weekly consultation rate for influenza-like-illness in England (http://www. hpa.org.uk/infections/topics_az/influenza/seasonal/ activity0506/Graph02.pdf). Accessed 1 October 2007.
    • 21. Dowell SF, et al. Seasonal patterns of invasive pneumococcal disease. Emerging Infectious Diseases 2003 ; 9 : 573-579.
    • 22. Hussain M, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiology and Infection 2005 ; 133 : 891-898.
    • 23. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001 ; 357 : 950-952.
    • 24. Pebody RG, Hellenbrand W, D'Ancona F, Ruutu P ; European Union funded Pnc-EURO contributing group. Pneumococcal disease surveillance in Europe. Eurosurveillance 2006 ; 11 : 171-178.
    • 25. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly : a comparison of meta-analyses. European Journal of Epidemiology 2004 ; 19 : 353-363.
    • 26. Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991 ; 325 : 1453-1460.
    • 27. Health Protection Agency. Pneumococcal vaccination uptake monitoring on behalf of the Department of Health (http://www.hpa.org.uk/infections/topics_az/ pneumococcal/vaccine/uptake_monitoring.htm). Accessed 20 August 2007.
    • 28. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Morbidity and Mortality Weekly Reports 2005 ; 54 : 893-897.
    • 29. Stephens DS, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine : population-based assessment. Lancet 2005 ; 365 : 855-863.
    • 30. Kayhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerging Infectious Diseases 1996 ; 2 : 289-298.
    • 31. Cartwright, K. Pneumococcal disease in western Europe : burden of disease, antibiotic resistance and management. European Journal of Pediatrics 2002 ; 161 : 188-195.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article